← Browse by Condition
Medical Condition

hypomethylating agent hma naive myelodysplastic syndromes mds

Total Trials
1
Recruiting Now
1
Trial Phases
Phase 3
NCT06465953 Phase 3
Recruiting

Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation

Enrollment
48 pts
Location
United States, Austr...
Sponsor
Institut de Recherches Interna...
View Trial →